Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Rivaroxaban ODT vs Film-coated Tablet in Healthy Japanese Males
NCT04511611Phase 1Completed
- Sponsor
- Bayer
- Start
- Jan 2019
- Primary completion
- Mar 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rivaroxaban in thromboembolism (4 arms), sponsored by Bayer. Primary endpoints: Maximum Plasma Concentration up to 48 hours and Area Under the Plasma Concentration-Time Curve from Time 0 to Last Quantifiable Concentration up to 48 hours. Started Jan 2019; status: completed.
02
Drugs
rivaroxaban
03
Conditions
thromboembolism
Beyond the preview
Go deeper on NCT04511611.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04511611.